BAC vs PFE: Which Is the Better Buy?

Side-by-side comparison of Bank of America Corporation and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals. Updated 2026-04-11.
Bank of America Corporation · Financial Services
$52.54
+7.3% upside to fair value
Grade B+
VS
Pfizer Inc. · Healthcare
$26.91
+30.1% upside to fair value
Med Conviction Grade B+
QuantHub Verdict
PFE has more upside to fair value (+30.1%). PFE trades at a lower forward P/E (9.5x). These are model outputs — not personalized investment advice. See all research →
Valuation & Fundamentals
Metric BAC PFE
Current Price $52.54 $26.91
Fair Value Estimate $56.39 $35.00
Upside to Fair Value +7.3% +30.1%
Market Cap $377.1B $153.0B
Forward P/E 12.1x 9.5x
EV / EBITDA 12.8x 13.8x
Price / Sales 2.0x 2.4x
Price / FCF 29.9x 16.8x
Revenue Growth YoY -0.5% -1.6%
Gross Margin 56.1% 70.3%
Operating Margin 19.7% 24.7%
Return on Equity 10.1% 9.0%
Dividend Yield 2.09% 6.4%
FCF Yield 3.35% 5.9%
Analyst Consensus Buy Hold
Investment Thesis
BAC — Bank of America Corporation
Bank of America is a top-two U.S. bank by assets with $3.4 trillion on its balance sheet, generating $30.5 billion in net income in 2025 on the back of 12.5% earnings growth. The bank benefits from scale in consumer deposits, a recovering investment banking franchise, and an expanding digital platform serving 47 million active users. At 12.7x trailing earnings and 1.97x sales, BAC trades at a fai…
PFE — Pfizer Inc.
Pfizer remains the world's largest traditional pharmaceutical company by non-COVID revenue, generating $62.6B in 2025 sales across oncology, cardiovascular, immunology, and vaccines. The stock trades at a P/S of 2.44x, still well below the 5-year median of 3.10x, driven by post-COVID revenue normalization, a $17-18B patent cliff spanning 2026-2028, and $61.6B in acquisition-related debt from Seag…
Accumulation Zones
Metric BAC PFE
Zone Low $42.29 $25.00
Zone High $47.93 $29.00
In Buy Zone? No Yes
← BAC Research    PFE Research →    All Research